Hanall Biopharma Co (XKRX:009420) Cash-to-Debt : 43.78 (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

Hanall Biopharma Co Cash-to-Debt Definition

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hanall Biopharma Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 43.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hanall Biopharma Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Hanall Biopharma Co's Cash-to-Debt or its related term are showing as below:

XKRX:009420' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 166.21 Max: No Debt
Current: 43.78

During the past 13 years, Hanall Biopharma Co's highest Cash to Debt Ratio was No Debt. The lowest was 0.68. And the median was 166.21.

XKRX:009420's Cash-to-Debt is ranked better than
85.97% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs XKRX:009420: 43.78

Hanall Biopharma Co Cash-to-Debt Historical Data

The historical data trend for Hanall Biopharma Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hanall Biopharma Co Cash-to-Debt Chart

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

167.96

164.47

60.35

41.16

43.78

Hanall Biopharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															41.16	46.28	42.65	55.13	43.78

Competitive Comparison of Hanall Biopharma Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hanall Biopharma Co Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's Cash-to-Debt falls into.

Hanall Biopharma Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hanall Biopharma Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	56497.111	/	(700.22	+	590.309)
	=	43.78

Hanall Biopharma Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	56497.111	/	(700.22	+	590.309)
	=	43.78

Hanall Biopharma Co (XKRX:009420) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hanall Biopharma Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co (XKRX:009420) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines